Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NovoCure Q4 EPS $(0.45) Beats $(0.52) Estimate, Sales $133.78M Beat $131.19M Estimate

Author: Benzinga Newsdesk | February 22, 2024 08:03am
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.52) by 13.46 percent. This is a 25 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $133.78 million which beat the analyst consensus estimate of $131.19 million by 1.98 percent. This is a 4.17 percent increase over sales of $128.43 million the same period last year.

Posted In: NVCR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist